Protagonist Therapeutics, Inc.
http://www.protagonist-inc.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Protagonist Therapeutics, Inc.
J&J/Protagonist’s JNJ-2113 Advancing To Pivotal Psoriasis Trial But Efficacy Questions Remain
The partners’ orally administered IL-23R inhibitor met all primary and secondary endpoints in a Phase IIb plaque psoriasis trial, justifying advancement to Phase III even though its efficacy fell short of available injectables according to cross-trial comparisons.
Protagonist Hopes For ‘Paradigm Change’ With Polycythemia Drug But Needs Phase III Safety Data
The company’s late-breaker data suggests it is on the path to success in polycythemia vera, but cancer fears must be addressed with ongoing longer-term study.
Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice